Medical resource utilisation and healthcare costs in patients with chronic hepatitis C viral infection and thrombocytopenia

Journal of Medical Economics

Volumn 14, Issue 2, 2011, Pages 194-206

  Poordad, Fred ^a,d   Theodore, Dickens ^b   Sullivan, Jane ^c   Grotzinger, Kelly ^b  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b GLAXOSMITHKLINE   (United States)

^c i3 Innovus   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Disease burden; Hepatitis C; Interferon; Medical resource utilisation; Platelet; Thrombocytopenia

Indexed keywords

ANTIVIRUS AGENT; INTERFERON;

ADULT; AMBULATORY CARE; ANEMIA; ANTIVIRAL THERAPY; ARTICLE; BLEEDING; CHRONIC LIVER DISEASE; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG COST; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FEMALE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEALTH INSURANCE; HEPATITIS C; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; LABORATORY DIAGNOSIS; LIVER CANCER; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; OUTPATIENT CARE; QUALITY OF LIFE; RETROSPECTIVE STUDY; THROMBOCYTE COUNT; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA;

ANTIVIRAL AGENTS; BLOOD TRANSFUSION; DISEASE PROGRESSION; FEMALE; HEALTH CARE COSTS; HEALTH RESOURCES; HEPATITIS C, CHRONIC; HUMANS; INPATIENTS; INSURANCE CLAIM REVIEW; INTERFERONS; MALE; MIDDLE AGED; OUTPATIENTS; PLATELET COUNT; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; RIBAVIRIN; THROMBOCYTOPENIA; UNITED STATES;

EID: 79953010856     PISSN: 13696998     EISSN: None     Source Type: Journal    
DOI: 10.3111/13696998.2011.562266     Document Type: Article

References (36)

1. Centers for Disease Control and Prevention. Viral hepatitis surveillance: esti-mates of disease burden from viral hepatitis. Available at: http://www.cdc.gov/hepatitis/HCV/HCVfaq.htm. Accessed October 20, 2010
2. Wasley A, Grytdal S, Gallagher K. Surveillance for acute viral hepatitis-United States, 2006. MMWR Surveill Summ 2008;57:1-24
3. Alter MJ, Kruszon-Moran D, Nainan OV, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999;341:556-62 (Pubitemid 29384163)
4. Armstrong GL, Wasley A, Simard EP, et al. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006; 144:705-14 (Pubitemid 46780630)
5. Centers for Disease Control and Prevention. National hepatitis C prevention strategy. Summer; 2001: http://www.cdc.gov/hepatitis/hcv/Strategy/ PDFs/NatHepCPrevStrategy.pdf. Accessed November 8, 2010
6. Centers for Disease Control and Prevention. Hepatitis C: fact sheet. June 2010: http://www.cdc.gov/hepatitis/hcv/pdfs/hepcgeneralfactsheet.pdf. Accessed November 8, 2010
7. Hoofnagle JH. Hepatitis C: the clinical spectrum of disease. Hepatology 1997;26(3 Suppl 1):15-20S
8. Xu J, Kochanek KD, Murphy SL, et al. Deaths: final data for 2007. Natl Vital Stat Rep 2010;58:1-135
9. Shiffman ML, Saab S, Feng S, et al. Liver and intestine transplantation in the United States, 1995-2004. Am J Transplant 2006;6:1170-87
10. Bashour FN, Teran JC, Mullen KD. Prevalence of peripheral blood cytopenias (hypersplenism) in patients with nonalcoholic chronic liver disease. Am J Gastroenterol 2000;95:2936-9
11. Bordin G, Ballare M, Zigrossi P, et al. Alaboratory and thrombo kinetic study of HCV-associated thrombocytopenia: a direct role of HCV in bone marrow exhaustion? Clin Exp Rheumatol 1995;13(Suppl 13):S39-43
12. Wang CS, Yao WJ, Wang ST, et al. Strong association of hepatitis C virus (HCV) infection and thrombocytopenia: implications from a survey of a com-munity with hyperendemic HCV infection. Clin Infect Dis 2004;39:790-6
13. Giannini E, Borro P, Botta F, et al. Serum thrombopoietin levels are linked to liver function in untreated patients with hepatitis C virus-related chronic hep-atitis. J Hepatol 2002;37:572-7 (Pubitemid 35305535)
14. NagamineT, OhtukaT, TakeharaK, et al.Thrombocytopeniaassociatedwith hepatitis C viral infection. J Hepatol1996;24:135-40
15. Sharma P, McDonald GB, Banaji M. The risk of bleeding after percutaneous liver biopsy: relation to platelet count. J Clin Gastroenterol1982;4:451-3 (Pubitemid 12027107)
16. Liangpunsakul S, Ulmer BJ, Chalasani N. Predictors and implications of severe hypersplenism in patients with cirrhosis. Am J Med Sci 2003; 326:111-16 (Pubitemid 37122293)
17. McVay PA, Toy PT. Lack of increased bleeding after liver biopsy in patients with mild hemostatic abnormalities. Am J Clin Pathol1990;94:747-53
18. Williford SK, Salisbury 3rd PL, Peacock Jr JE, et al. The safety of dental extractions in patients with hematologic malignancies. J Clin Oncol 1989; 7:798-802 (Pubitemid 19145603)
19. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-82
20. Shimakami T, Lanford RE, Lemon SM. Hepatitis C: recent successes and continuing challenges in the development of improved treatment modalities. Curr Opin Pharmacol 2009;9:537-44
21. Ong JP, Younossi ZM. Managing the hematologic side effects of antiviral therapy for chronic hepatitis C: anemia, neutropenia, and thrombocytopenia. Cleve Clin J Med 2004;71(Suppl 3):S17-21 (Pubitemid 41315602)
22. Strader DB, Wright T, Thomas DL, et al. Diagnosis, management, and treat-ment of hepatitis C. Hepatology 2004;39:1147-71
23. Poordad F. Thrombocytopenia in chronic liver disease. Aliment Pharmacol Ther. 2007;26(Suppl 1):5-11
24. Weksler BB. The pathophysiology of thrombocytopenia in hepatitis C virus infection and chronic liver disease. Aliment Pharmacol Ther 2007; 26(Suppl 1):13-19 (Pubitemid 47631869)
25. Accessed April 29 2008, Centers for Disease Control and Prevention. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic dis-ease. MMWR Recomm Rep [May 2; 2001:http://www.ncbi. nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt= Citation&list-uids=9790221. Accessed April 29, 2008
26. Dieterich DT, Spivak JL Hematologic disorders associated with hepatitis C virus infection and their management. Clin Infect Dis 2003;37:533-41 (Pubitemid 37011777)
27. McCullough J. Current issues with platelettransfusion in patients with cancer. Semin Hematol 2000;37(2 Suppl 4):3-10 (Pubitemid 30332058)
28. Rinder HM, Arbini AA, Snyder EL. Optimal dosing and triggers for prophylactic use of platelet transfusions. Curr Opin Hematol1999;6:437-41 (Pubitemid 29503155)
29. McHutchison JG, Manns M, Patel K, et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 2002;123:1061-9
30. Shiffman ML, Ghany MG, Morgan TR, et al. Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis C Gastroenterology 2007;132:103-12 (Pubitemid 46127673)
31. Dienstag JL, McHutchison JG. American Gastroenterological Association technical review on the management of hepatitis C. Gastroenterology 2006;130:231-64; quiz 214-37 (Pubitemid 43049856)
32. Brown Jr RS. A pharmacoeconomic analysis of thrombocytopenia in chronic liver disease. Aliment Pharmacol Ther 2007;26(Suppl 1):41-8 (Pubitemid 47631864)
33. Pegasys® (peginterferon alfa-2a). Full prescribing information. Hoffmann-La Roche Inc Nutley, NJ 2008
34. PegIntron® (peginterferon alfa-2b). Full prescribing information. Schering-Plough Corporation. Kenilworth, NJ 2009
35. Armstrong GL, Wasley A, Simard EP, et al. The prevalenceo f hepatitisCvirus infection in the United States, 1999 through 2002. Ann Intern Med. 2006; 144:705-14 (Pubitemid 46780630)
36. Wasley A, Miller JT, Finelli L. Surveillance for acute viral hepatitis\United States, 2005. MMWR Surveill 2007;56:1-24